These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9258982)

  • 1. Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet.
    Lukkari E; Aranko K; Juhakoski A; Hakonen T; Neuvonen PJ
    Pharmacol Toxicol; 1997 Jul; 81(1):31-4. PubMed ID: 9258982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of food on the bioavailability of oxybutynin from a controlled release tablet.
    Lukkari E; Castrèn-Kortekangas P; Juhakoski A; Löyttyniemi E; Aranko K; Neuvonen PJ
    Eur J Clin Pharmacol; 1996; 50(3):221-3. PubMed ID: 8737763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite.
    Lukkari E; Juhakoski A; Aranko K; Neuvonen PJ
    Eur J Clin Pharmacol; 1997; 52(5):403-6. PubMed ID: 9272412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride.
    Sathyan G; Chancellor MB; Gupta SK
    Br J Clin Pharmacol; 2001 Oct; 52(4):409-17. PubMed ID: 11678784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
    Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
    Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids.
    Lukkari E; Hakonen T; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Jan; 53(5):351-4. PubMed ID: 9516036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
    Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
    Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation.
    Sathyan G; Hu W; Gupta SK
    J Clin Pharmacol; 2001 Feb; 41(2):187-92. PubMed ID: 11210400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
    Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
    J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients.
    Nilsson CG; Lukkari E; Haarala M; Kivelä A; Hakonen T; Kiilholma P
    Neurourol Urodyn; 1997; 16(6):533-42. PubMed ID: 9353802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin.
    Birns J; Lukkari E; Malone-Lee JG
    BJU Int; 2000 May; 85(7):793-8. PubMed ID: 10792154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
    Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
    Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Population Pharmacokinetic Model of (R)- and (S-) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers.
    Kretschmar M; Suleiman AA; Krause P; Albrecht U; Stein R; Rubenwolf P; Fuhr U; Taubert M
    J Clin Pharmacol; 2021 Jul; 61(7):961-971. PubMed ID: 33368382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.
    Sathyan G; Dmochowski RR; Appell RA; Guo C; Gupta SK
    Clin Pharmacokinet; 2004; 43(14):1059-68. PubMed ID: 15530134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive determination of oxybutynin and desethyloxybutynin in dog plasma by LC-ESI/MS/MS.
    Kim H; Han SB
    J Pharm Biomed Anal; 2003 Feb; 31(2):341-9. PubMed ID: 12609673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release oxybutynin.
    Comer AM; Goa KL
    Drugs Aging; 2000 Feb; 16(2):149-55; discussion 156-7. PubMed ID: 10755330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
    Dmochowski R; Chen A; Sathyan G; MacDiarmid S; Gidwani S; Gupta S
    J Clin Pharmacol; 2005 Aug; 45(8):961-8. PubMed ID: 16027408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxybutynin topical and transdermal formulations: an update.
    Staskin DR; Salvatore S
    Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.